Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma

甲状腺癌 医学 危险分层 淋巴结 内科学 肿瘤科 内分泌学 甲状腺
作者
Eyun Song,Jong Hwa Ahn,Dong Eun Song,Won Woong Kim,Min Ji Jeon,Tae‐Yon Sung,Tae Yong Kim,Ki‐Wook Chung,Won Bae Kim,Young Kee Shong,Suck Joon Hong,Yu‐Mi Lee,Won Gu Kim
出处
期刊:Clinical Endocrinology [Wiley]
卷期号:92 (4): 358-365 被引量:5
标识
DOI:10.1111/cen.14115
摘要

Evidence for American Thyroid Association (ATA) risk stratification stems largely from studies involving patients undergoing total thyroidectomy. We aimed to assess the risk of recurrence according to the present ATA risk stratification system in patients who underwent lobectomy.Retrospective cohort study.Patients who underwent thyroid lobectomy for 1-4 cm-sized papillary thyroid carcinoma (n = 571).Disease-free survival (DFS) was compared according to the ATA risk stratification, and specific lymph node (LN) characteristics were evaluated to modify the ATA criteria with a higher predictability for recurrence.Based on the ATA risk stratification, 439 patients (61.1%) were classified into intermediate- or high-risk group, and consideration for completion thyroidectomy is suggested by ATA guidelines for these patients. However, no significant differences were found in DFS among the low-, intermediate- and high-risk groups (P = .9). In contrast, when patients were stratified according solely to the LN criteria from the ATA risk stratification, only 127 patients (22.2%) had intermediate risk (intermediate-N1a) and exhibited significantly poorer DFS than those with N0 disease (P = .035). Modifying the intermediate-N1a criteria by adding the extranodal extension (ENE) status and omitting the clinical nodal disease enabled the subclassification of 19 patients (3%) with a high risk for recurrence.The present study suggests that risk stratification based solely on LN metastases is more reasonable for predicting structural persistence/recurrence following lobectomy than that based on the overall ATA criteria. Considering the ENE status can assist in selecting patients with a high risk of recurrence to minimize further treatments.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小蘑菇应助caitSith采纳,获得10
2秒前
凡凡完成签到,获得积分10
2秒前
yan发布了新的文献求助30
3秒前
科研通AI2S应助大力的图图采纳,获得10
4秒前
饺子完成签到,获得积分10
4秒前
4秒前
九月初五完成签到,获得积分10
4秒前
数星星发布了新的文献求助10
5秒前
明亮荔枝应助哦吼采纳,获得10
5秒前
pluto应助fafafa采纳,获得10
6秒前
6秒前
曾经的臻发布了新的文献求助10
7秒前
量子星尘发布了新的文献求助10
7秒前
苏东方完成签到,获得积分10
8秒前
量子星尘发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
斐波拉切土豆完成签到 ,获得积分10
10秒前
lemishui完成签到,获得积分10
11秒前
火禾心羽发布了新的文献求助10
13秒前
深情安青应助哦吼采纳,获得10
13秒前
all661发布了新的文献求助10
15秒前
cadet发布了新的文献求助10
15秒前
16秒前
17秒前
20秒前
21秒前
研友_85rJEL发布了新的文献求助10
22秒前
祎祎完成签到,获得积分10
23秒前
科研通AI6.1应助顺顺过过采纳,获得10
23秒前
jackie able发布了新的文献求助10
24秒前
现代书雪发布了新的文献求助10
24秒前
温婉发布了新的文献求助10
24秒前
小y完成签到 ,获得积分10
26秒前
量子星尘发布了新的文献求助10
26秒前
伶俐妙海发布了新的文献求助100
27秒前
直率雨柏完成签到,获得积分10
28秒前
COIN_77完成签到 ,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Introduction to strong mixing conditions volume 1-3 5000
Ägyptische Geschichte der 21.–30. Dynastie 2500
Human Embryology and Developmental Biology 7th Edition 2000
The Developing Human: Clinically Oriented Embryology 12th Edition 2000
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 2000
„Semitische Wissenschaften“? 1510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5741989
求助须知:如何正确求助?哪些是违规求助? 5404909
关于积分的说明 15343645
捐赠科研通 4883431
什么是DOI,文献DOI怎么找? 2625021
邀请新用户注册赠送积分活动 1573893
关于科研通互助平台的介绍 1530838